Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Parvus Therapeutics

- PMLiVE

Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration

There are more than three million people affected by IBD globally, with a need to improve current treatments

- PMLiVE

AbbVie reaches agreement for affordable prescription drugs with US government

The pharma company has also pledged a $100bn investment in US infrastructure over the next decade

- PMLiVE

Lilly’s Omvoh shows improved outcomes in ulcerative colitis

The phase 3 trial results demonstrated improved symptomatic, clinical and quality-of-life measures

- PMLiVE

AbbVie/Genmab’s lymphoma drug shows promise in phase 3 combination trial

Follicular lymphoma affects around 15,000 people in the US every year

- PMLiVE

AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

Around 700,000 people in the US are living with some form of the autoimmune disease

- PMLiVE

AbbVie’s Elahere granted MHRA approval to treat platinum-resistant ovarian cancer

Approximately 7,500 people are diagnosed with ovarian cancer every year in the UK

- PMLiVE

Abivax shares positive late-stage results for obefazimod in ulcerative colitis

Inflammatory bowel disease affects nearly one in every 100 people in the US

- PMLiVE

AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

- PMLiVE

AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition

The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases

- PMLiVE

Eli Lilly’s Omvoh recommended by NICE to treat Crohn’s disease in adults

Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

- PMLiVE

J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis

Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

- PMLiVE

AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies

The companies will focus on developing therapeutics across neuroscience, immunology and oncology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links